Osaicam posaconazole injection is about to pass the consistency evaluation

Recently, NMPA official website data shows that Osaikon’s posaconazole injection 3 types of imitation listing applications have entered the "under review" status, and it is expected to win the first domestic imitation + first review.

Figure 1: Registration progress of Osaikon's posaconazole injection

Source: NMPA official website

Figure 2: Sales of posaconazole

Source: Mi Nei.

Table 1: Applications for imitation of posaconazole on the market

Source: Meinenet MED2.

In terms of domestic generic drugs, Shanghai Xuantai Pharmaceutical Technology's posaconazole enteric-coated tablets, which were declared and marketed in accordance with 4 types of generics, were contracted in February 2019, and were included in the priority review in September of the same year.

If Osaikon succeeds in winning the first domestic imitation of posaconazole injection, it can form a combined attack with posaconazole enteric-coated tablets, and Merck’s monopoly of the market is expected to be broken.